| Antitope Ltd, Announces Research Agreement with China Synthetic Rubber Corporation, Taipei, Taiwan |
|
23rd January 2008 - Antitope Ltd., a privately-held antibody and protein engineering company, today announced a research agreement with the China Synthetic Rubber Corporation (CSRC). Under the Agreement, Antitope will apply Composite Human AntibodyTM technology to produce two fully humanized antibodies for use in oncology.
"We are very happy to have signed this agreement with a company as dynamic as CSRC," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Ltd. "This partnership utilizes Antitope's expertise in non-immunogenic fully humanized antibodies, and will assist CSRC to generate therapies stemming from their novel discovery pipeline in relation to oncology." Leslie Koo, chairman of CSRC, reports, "Antitope is recognized as a leading antibody and protein engineering company. I believe that Antitope's expertise and commitment provide the best opportunity to make humanized antibodies for use in our oncology project." About Antitope Antitope Ltd. is a Cambridge, UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary technology builds upon the previous pioneering work of its founders in the detection and removal of T cell epitopes in antibodies/proteins through humanization and de-immunisation technologies. Antitope are a privately-held company and have established multiple worldwide commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit http://www.antitope.co.uk/. About China Synthetic Rubber Corporation China Synthetic Rubber Corporation (CSRC) was incorporated on June 15, 1973. By December 31, 2005, CSRC had capital of $4,377,056,000 NT. CSRC is a public company traded on the Taiwan Stock Exchange. CSRC's primary business is research, development and manufacturing of carbon black used in tires and other applications. CSRC operates plants in Taiwan and its affiliates operate plants in China, US and India. Since 2000, CSRC also owns equity of 85.31% in Synpac (NC, USA) whose main business interest is in biotechnology. For further information contact: Dr Neil Butt, Business Development Director Antitope Ltd Tel: +44 (0)1223 496190 Email: neil.butt@antitope.co.uk Contact from CSRC: T. L. Wong, President China Synthetic Rubber Corporation Tel: +886-2531-6556 Email: tlwong@csrcgroup.com |